Biotech

All Articles

Sanofi flunks MS study, dealing another impact to Denali pact

.Sanofi has quit a stage 2 hardship of Denali Therapeutics-partnered oditrasertib in several scleros...

Turnstone gives up 60%, shakes up C-suite to extend cash money

.Turnstone Biologics is lessening its head count by 60% as well as agitating its own C-suite so as t...

Gilead gives up on $15M MASH wager after reviewing preclinical information

.In a year that has actually found a confirmation as well as a raft of readouts for metabolic dysfun...

Texas biotech axes cancer treaty, pins wishes on weight problems

.Alaunos Therapeutics is actually axing a contract along with Precigen, surrendering licensing civil...

Capricor allotments a lot more information for DMD therapy after launching BLA

.Capricor Therapeutics is taking a victory lap for their stage 2 Duchenne muscular dystrophy (DMD) t...

FDA areas Kezar lupus trial in grip adhering to 4 individual deaths

.The FDA has placed Kezar Life Sciences' lupus trial on hold after the biotech warned four fatalitie...

Phase 3 Historian Stone trial reaches SMA target, sending stock up 200%

.A period 3 test of Historian Stone's vertebral muscle degeneration (SMA) applicant has reached its ...

CAMP 4 is actually latest to eye IPO, while Upstream point out $182M plan

.RNA biotech CAMP4 Therapeutics has marked out plans for a $67 thousand IPO, along with inflammation...

Galecto gets leukemia medication, loses bone tissue cancer cells resource in pivot

.A year after the failing of an idiopathic pulmonary fibrosis applicant delivered Galecto on a searc...

Judo throws down $100M to knock senseless kidney disease

.Taking the floor covering is Judo Biography, an ambitious biotech armed with $one hundred million t...